GLP-1 Therapy and Lifestyle Changes Used to Manage Morbid Obesity in Patient With Atrial Fibrillation, Osteoarthritis and Sleep Apnea

A new case report highlights an individualized approach to managing morbid obesity in a patient living with several complex health conditions, including paroxysmal atrial fibrillation, severe osteoarthritis and obstructive sleep apnea. The case involved the initiation of glucagon-like peptide-1 receptor agonist therapy alongside lifestyle modifications, illustrating how obesity treatment may need to be tailored when multiple comorbidities are present.

The peer-reviewed, open-access case report was authored by Brian Morris and published in Cureus on September 15, 2026. Cureus lists the report within its preventive medicine and internal medicine collections. 1

Why This Obesity Case Is Notable

Managing severe obesity can become considerably more complicated when a patient also has cardiovascular disease, painful joint disease and sleep-related breathing problems.

In this case, the patient had morbid obesity, paroxysmal atrial fibrillation, severe osteoarthritis and obstructive sleep apnea. These conditions can overlap in ways that affect mobility, sleep, cardiovascular health and the ability to maintain lifestyle changes.

The report focuses on the initiation of a GLP-1 receptor agonist together with lifestyle modifications rather than presenting medication as a standalone approach.

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 receptor agonists, are medicines that act on pathways involved in appetite regulation, satiety, glucose metabolism and gastrointestinal function.

Some medicines in this broader class are used for type 2 diabetes, while certain GLP-1-based treatments are approved for chronic weight management in eligible patients.

By influencing appetite and food intake, these medicines can help some people achieve weight loss when incorporated into an appropriate medical treatment plan. Lifestyle measures, including nutrition and physical activity, remain important components of comprehensive obesity care.

Severe Osteoarthritis Can Make Weight Loss More Difficult

One of the challenges highlighted by the case is severe osteoarthritis.

Osteoarthritis can cause pain, stiffness and reduced mobility. For a person with severe obesity, painful weight-bearing joints may make conventional forms of exercise particularly difficult.

This creates a potentially challenging cycle: excess body weight can increase mechanical stress on joints, while joint pain can make physical activity harder to maintain.

For such patients, lifestyle modification may need to be individualized. Depending on a person’s medical condition, lower-impact activities, physical therapy or supervised exercise may be more practical than high-impact workouts.

Obstructive Sleep Apnea and Obesity

The patient’s obstructive sleep apnea adds another important dimension to the case.

Obstructive sleep apnea occurs when the upper airway repeatedly becomes partially or completely blocked during sleep. These episodes can disrupt sleep and may cause intermittent reductions in blood oxygen levels.

Obesity is an important risk factor for obstructive sleep apnea, and weight management can form part of treatment for people with obesity-related OSA.

The connection is particularly relevant in a patient who has several overlapping cardiometabolic conditions because sleep apnea itself can contribute to cardiovascular stress.

Why Atrial Fibrillation Matters in This Case

Paroxysmal atrial fibrillation is another significant condition mentioned in the case report.

Atrial fibrillation is an irregular heart rhythm that can occur intermittently in its paroxysmal form. Management typically involves assessing the individual’s cardiovascular and stroke risks and determining appropriate treatment.

The presence of atrial fibrillation means that an obesity-management strategy needs to be considered in the context of the patient’s overall cardiovascular health.

However, the case report should not be interpreted as evidence that GLP-1 receptor agonists are a treatment for atrial fibrillation itself. The focus of the report is the management of morbid obesity in a patient who also has atrial fibrillation and other significant conditions.

Why Lifestyle Modification Was Combined With Medication

The case is particularly relevant to the growing discussion around combining anti-obesity medication with lifestyle interventions.

Medication can address biological mechanisms involved in appetite and weight regulation, while lifestyle changes can target dietary patterns, physical activity, behavioural habits and long-term weight maintenance.

A combined approach may therefore provide a broader framework for obesity management. The exact lifestyle programme, however, needs to reflect an individual’s mobility, cardiovascular status, sleep health and other medical considerations.

Weight Management Is About More Than the Number on the Scale

For people with severe obesity and multiple comorbidities, clinically meaningful weight management may have implications beyond body weight itself.

Reducing excess weight can potentially improve physical function and make movement easier. It may also influence obesity-associated conditions such as sleep apnea and osteoarthritis symptoms.

This is one reason obesity is increasingly treated as a chronic disease requiring a comprehensive, long-term management strategy rather than simply a short-term diet or exercise programme.

GLP-1 Treatment Requires Medical Supervision

GLP-1 receptor agonists are prescription medicines and are not suitable for everyone. A healthcare professional needs to consider a patient’s medical history, existing medications, treatment goals and potential adverse effects before prescribing them.

This is especially important when obesity occurs alongside cardiovascular conditions, significant joint disease and sleep apnea.

Patients should also avoid using an individual case report as a basis for starting or changing prescription medication without medical advice.

What This Case Report Can—and Cannot—Show

A case report provides a detailed description of an individual clinical experience. It can highlight a treatment approach and raise questions for further research, but it cannot establish how effective a treatment will be across a larger population.

There is no large comparison group in a single-patient case report, meaning observed changes cannot necessarily be attributed entirely to the GLP-1 receptor agonist. Lifestyle modifications, other treatments and individual patient factors may also contribute to clinical outcomes.

Therefore, the report should be viewed as a clinical example of individualized obesity management rather than evidence that the same treatment will produce identical results in every patient.

Why Individualized Obesity Treatment Matters

The case illustrates an important issue in obesity medicine: patients do not necessarily face the same barriers to weight management.

Someone with severe osteoarthritis may have difficulty performing conventional exercise. Another patient may have sleep apnea that affects sleep quality and daytime functioning. Someone with atrial fibrillation may require additional cardiovascular considerations when increasing physical activity.

These overlapping factors can make a one-size-fits-all approach inappropriate. Treatment plans may instead need to combine medication, nutrition, physical activity, behavioural strategies and management of underlying conditions.

Key Takeaways

• The case report was published in Cureus on September 15, 2026.
• Brian Morris is the author of the report. 2
• The patient had morbid obesity along with paroxysmal atrial fibrillation, severe osteoarthritis and obstructive sleep apnea.
• The reported treatment approach involved initiating a GLP-1 receptor agonist alongside lifestyle modifications.
• Severe osteoarthritis can make conventional physical activity and weight-management strategies more challenging.
• Obesity and obstructive sleep apnea frequently overlap, making weight management relevant to comprehensive care.
• Atrial fibrillation adds cardiovascular considerations when developing an individualized treatment plan.
• Because this is a single-patient case report, its findings cannot establish the effectiveness of GLP-1 therapy for the wider population.

Bottom Line

A new Cureus case report illustrates how GLP-1 receptor agonist therapy can be incorporated with lifestyle modifications when managing morbid obesity in a patient with multiple complex conditions. The combination of obesity, paroxysmal atrial fibrillation, severe osteoarthritis and obstructive sleep apnea creates challenges that require an individualized approach.

The report adds to the clinical discussion surrounding comprehensive obesity treatment, but its findings should be interpreted in context. A case report cannot determine how effective the treatment will be for other patients, and GLP-1 medicines should be used only under appropriate medical supervision.